Ahrén B, Andrén-Sandberg A
Department of Surgery, Lund University, Sweden.
Res Exp Med (Berl). 1993;193(1):21-6. doi: 10.1007/BF02576207.
Pancreatic cancer develops at approximately 25 weeks after 6 weeks of weekly subcutaneous administration of N-nitrosobis (2-oxypropyl)amine in the Syrian golden hamster. We studied the glucose tolerance and insulin secretion during the development of pancreatic cancer in this model. Every 6th week after start of treatment, glucose was infused intravenously for 30 min (10 mg/min). It was found that the glucose tolerance and glucose-stimulated insulin secretion were normal at 6, 12, and 18 weeks after start of treatment compared with age-matched saline-injected controls. By contrast, after 24, 30, and 42 weeks an exaggerated plasma-glucose response and a concomitant impaired plasma-insulin response occurred during the glucose infusion (P < 0.05). We therefore conclude that the development of pancreatic cancer in this model is accompanied by glucose intolerance and impaired insulin secretion, and that these effects occur concomitantly with the development of cancer.
在叙利亚金仓鼠中，每周皮下注射N-亚硝基双（2-氧丙基）胺6周后，约25周时会发生胰腺癌。我们在该模型中研究了胰腺癌发生过程中的葡萄糖耐量和胰岛素分泌情况。治疗开始后每隔6周，静脉输注葡萄糖30分钟（10毫克/分钟）。结果发现，与年龄匹配的注射生理盐水对照组相比，治疗开始后6、12和18周时，葡萄糖耐量和葡萄糖刺激的胰岛素分泌均正常。相比之下，在24、30和42周后，葡萄糖输注期间出现了过度的血浆葡萄糖反应以及伴随的血浆胰岛素反应受损（P<0.05）。因此，我们得出结论，该模型中胰腺癌的发生伴随着葡萄糖不耐受和胰岛素分泌受损，且这些影响与癌症的发生同时出现。
